Malíková, Karolína* Dotaz Zobrazit nápovědu
This article introduces a network data set on the friendships and group work interactions among a convenience sample of 276 Czech Grade 6 students from twelve classrooms, supported by student-level demographic, literacy, motivation, and classroom communication data. Gathered longitudinally at the beginning and end of the 2021/2022 school year, the data provide a relational insight into the nature and evolution of early adolescents' friendships. Moreover, the data provide a unique relational and temporal insight into the verbal interaction of students during classroom group work. This dataset constitutes a valuable resource for educational researchers interested in studying classroom group work as well as for social network scientists studying dynamic social networks.
- Publikační typ
- časopisecké články MeSH
K desátému výročí komplexní léčby Dětské obezitologické ambulance jsme vyhodnotili efektivitu a výkonnost ambulance. Za deset let prošlo edukační fází ambulance 1012 pacientů a za posledních 5 let jsme vyhodnotili skupinu 656 pacientů, z nichž bylo 3,1% klientů se sekundární obezitou, 40,4% s primární obezitou a 56,5% s primární obezitou s komplexními metabolickými změnami. Ve skupině primární obezity byli chlapci zastoupeni 53,9% a dívky 46,1% se vstupním BMI v rozmezí nadváhy u 12,5%, nezávažné obezity u 20%, závažné obezity u 35,2%, těžké obezity u 20,6% a monstrózní obezity u 11,3% dětí. Kompletní program ambulance absolvovaly ¾ klientů. Výsledky jsme vyhodnotili u 184 dětí s průměrnou délkou sledování 1¾ roku. Jejich vstupní BMI bylo na úrovni závažné obezity 2,8 SD BMI. Všichni pacienti prošli terapeutickou redukční fází s průměrnou redukcí –0,57 SD BMI. Průměrná konečná redukce byla –0,59 SD BMI. Skladba klientů, komplexnost služeb a dosažené výsledky ambulance jsou na úrovni světových center dětské obezitologie při významně nižších nákladech. Žádoucí je včas zhodnotit zdravotní rizika rozvíjející se nadváhy a stanovit režim sledování a léčby v rámci navržené celoplošné koncepce dětské obezitologie. Naše každodenní praxe přes uspokojivé výsledky prokazuje, že nejjednodušší a nejúčinnější léčbou dětské obezity je její prevence.
We evaluated the effectiveness and efficiency after 10th year of implementation of comprehensive treatment practice at children obesity clinic. The number of patients who have gone through the educational phase of the protocol, has doubled to 656 clients in comparison with the first five-year period. 3% of clients had been diagnosed with secundar obesity, 40% with primar obesity and 57% with primar obesity with complex metabolic changes. In the group of common obesity, boys represented 54% and girls 46%. The entry SDS BMI parameters: overweight 13%, non-severe obesity I. grade 20%, severe obesity II. grade 35%, morbid obesity III. grade 21% and a monstrous obesity IV. grade 11% of children. 75% of clients completed the outpatient clinic program. We have processed the results of 184 children with a mean follow of 1¾ year. Their entry SDS BMI was at the level of morbid obesity with SDS BMI 2.8. All patients passed through the therapeutic reduction phase with an average reduction of SDS BMI –0.57. Average final reduction was SDS BMI –0.59. Types of clients, complexity of services and achievements of outpatient clinic are at the level of the world‘s successful child obesitology centers at significantly lower cost. Timely assessment of the health risks of developing overweight and its diagnosis is desirable and establishment of a regime of monitoring and treatment within the proposed national concept of child obesitology. Our daily practice despite satisfactory results prove that the simplest and most effective treatment of childhood obesity is its prevention.
- MeSH
- ambulantní péče MeSH
- dítě MeSH
- hodnocení výsledků zdravotní péče * statistika a číselné údaje MeSH
- kognitivně behaviorální terapie MeSH
- lidé MeSH
- mladiství MeSH
- obezita * dietoterapie prevence a kontrola psychologie MeSH
- předškolní dítě MeSH
- služby preventivní péče MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Klíčová slova
- gen PROP1,
- MeSH
- efekt zakladatele MeSH
- genetická predispozice k nemoci MeSH
- haplotypy MeSH
- homeodoménové proteiny genetika MeSH
- hypofyzární hormony * nedostatek MeSH
- hypopituitarismus genetika MeSH
- lidé MeSH
- multicentrické studie jako téma MeSH
- mutace * genetika MeSH
- mutační analýza DNA MeSH
- prevalence MeSH
- transkripční faktor Pit-1 genetika MeSH
- Check Tag
- lidé MeSH
BACKGROUND: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action. OBJECTIVE: The absorbtion of rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration. Peroral bioavailability is high (80-100 %) and pharmacokinetic variability is considered to be moderate (coefficient of variation 30-40 %). This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban. METHOD: Dosing regimen of rivaroxaban was derived from pharmacologic data of the development program aimed to gain strong antithrombotic drug and balance between efficacy and risk of bleeding in patients. Results of doseranging trials, pharmacokinetic models and randomised studies of phase III advocate the use of such schemes in everyday practice. RESULTS: The drug has been manufactured to fulfill clinical requirements in a variety of indications in adults: prophylaxis of venous thromboembolism (VTE) following elective knee or hip replacement surgical intervention, therapy and secondary prophylaxis of VTE, prophylaxis of ischemic stroke and embolism in individuals diagnosed with nonvalvular atrial fibrillation (NVAF) with risky characteristics, and in Europe the prophylaxis of atherothrombotic episodes following an acute coronary syndrome in subjects with increased levels of cardiac biomarkers. CONCLUSION: Rivaroxaban may offer benefit in many clinical situations. In comparison with low molecular weight heparin and fondaparinux requiring subcutaneous way of administration, and with vitamin K antagonists (VKAs), which require regular monitoring of international normalized ratio, rivaroxaban is relatively easy to use. However, adjustments of dose are needed in individuals with impaired renal functions.
- MeSH
- inhibitory faktoru Xa * farmakokinetika farmakologie MeSH
- lékové interakce MeSH
- lidé MeSH
- rivaroxaban * farmakokinetika farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Two variants (c.[301_302delAG];[301_302delAG] and c.[150delA];[150delA]) in the PROP1 gene are the most common genetic causes of recessively inherited combined pituitary hormones deficiency (CPHD). Our objective was to analyze in detail the origin of the two most prevalent variants. In the multicentric study were included 237 patients with CPHD and their 15 relatives carrying c.[301_302delAG];[301_302delAG] or c.[150delA];[150delA] or c.[301_302delAG];[ 150delA]. They originated from 21 different countries worldwide. We genotyped 21 single-nucleotide variant markers flanking the 9.6-Mb region around the PROP1 gene that are not in mutual linkage disequilibrium in the general populations--a finding of a common haplotype would be indicative of ancestral origin of the variant. Haplotypes were reconstructed by Phase and Haploview software, and the variant age was estimated using an allelic association method. We demonstrated the ancestral origin of both variants--c.[301_302delAG] was carried on 0.2 Mb-long haplotype in a majority of European patients arising ~101 generations ago (confidence interval 90.1-116.4). Patients from the Iberian Peninsula displayed a different haplotype, which was estimated to have emerged 23.3 (20.1-29.1) generations ago. Subsequently, the data indicated that both the haplotypes were transmitted to Latin American patients ~13.8 (12.2-17.0) and 16.4 (14.4-20.1) generations ago, respectively. The c.[150delA] variant that was carried on a haplotype spanning about 0.3 Mb was estimated to appear 43.7 (38.4-52.7) generations ago. We present strong evidence that the most frequent variants in the PROP1 gene are not a consequence of variant hot spots as previously assumed, but are founder variants.
